Developer docs
API playgroundTry for free, no card

Search company profiles

TransCure bioServices

Full company profile

uuid0003n13

Namestring
TransCure bioServices
Legal namestring
TransCure BioServices SAS
Company typeenum
Private
Founded yearint
2012
Descriptiontext

TransCure bioServices SAS is a France-based preclinical Contract Research Organization founded in 2012 and headquartered in Archamps (registered at the Registry of Thonon-les-Bains). The company specializes in humanized mouse models for translational drug development, offering four core model classes: CD34+ humanized immune system mice, humanized liver mice, double humanized mice combining both systems, and conventional immunodeficient/immunocompetent mice. These models are applied across a portfolio of disease models spanning oncology (human CDX, human PDX, syngeneic), inflammatory disease (IBD, MASH, GvHD, lung inflammation), and infectious disease (HIV, HBV), complemented by hepatotoxicity and immunotoxicity screening services.

The underlying technology platform combines wet-lab biology with an instrumentation stack including three Thermo Fisher Attune NxT flow cytometers, a BD FACS Melody cell sorter, an Aperio Versa digital pathology scanner, a Vilber Newton bioluminescence imaging system, and primary cell culture assays for in vitro mechanism-of-action work. Study operations are supported by RADAR, a custom in-house tracking software for traceability and reproducibility. The company holds AAALAC International accreditation (since 2022), is a GIRCOR charter signatory, and operates a GLP-aligned quality system.

The business model is project-based B2B preclinical CRO services sold through a consultative, sales-led motion targeting biotech and pharmaceutical enterprise clients, with services covering advanced therapeutic modalities including bi-specific antibodies, CAR-T, and antibody-drug conjugates. All 70 collaborators are based in France, and the operating geography has historically been Europe-focused. On January 20, 2026, Taconic Biosciences announced its acquisition of TransCure bioServices, establishing a fully integrated translational research platform that combines Taconic's global rodent model production infrastructure with TransCure's disease-specific translational pharmacology, flow cytometry, and in vivo capabilities.

Short descriptiontext

TransCure bioServices is a France-based preclinical CRO founded in 2012 that provides humanized mouse models and translational pharmacology services to biotech and pharmaceutical clients developing advanced therapeutics, including antibodies, CAR-T, and ADCs.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersArchamps, France
HQ citystring
Archamps
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
humanized mouse models, preclinical CRO services, translational pharmacology, immunotoxicity assessment, oncology disease models
Industry1 code
PRIMARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical CRO Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical CRO Services
TypeProfessional Services
Description

Contract research organization providing preclinical studies using humanized mouse models for biotech and pharmaceutical companies. Services include translational pharmacology, flow cytometry, and advanced in vivo study capabilities. Revenue generated through project-based contracts for specific preclinical studies.

businesswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

TransCure bioServices is a preclinical contract research organization that designs and executes in vivo pharmacology studies using proprietary humanized and conventional mouse models. It delivers customized preclinical packages — including model selection, study execution, and readouts such as flow cytometry, immunohistochemistry, and in vivo imaging — for biotech, pharmaceutical, and academic sponsors advancing novel therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Humanized mice engraftment with complete human immune system reconstitution including mature T cells, NK cells, and macrophages
+1 more record
Product overview1 text field

TransCure bioServices is a preclinical Contract Research Organization (CRO) offering a portfolio of humanized and conventional mouse models for translational research. The core product line includes four distinct mouse model types: CD34+ Humanized Mouse, Humanized Liver Mouse Model, Double Humanized Mouse Model, and Conventional Mouse Models. These models are applied across multiple disease model categories—Oncology (Human CDX, Human PDX, Syngeneic), Inflammatory diseases (IBD, MASH, GvHD, Lung Inflammation), and Infectious diseases (HIV, HBV). The company also provides dedicated toxicity assessment services (Hepatotoxicity, Immunotoxicity) and general preclinical CRO services. The offering is a services-based portfolio rather than a unified software platform, with models validated over 12 years of experience, now integrated with Taconic Biosciences following acquisition.

Product and service10 records
1CD34+ Humanized Mouse Model
CategoryHumanized Mouse Model
Description

Humanized mouse model engrafted with human CD34+ hematopoietic stem cells, supplied for and used within preclinical efficacy, immunotoxicity, and mechanism-of-action studies for biotech, pharma, and academic sponsors.

2Humanized Liver Mouse Model
CategoryHumanized Mouse Model
Description

Mouse model harboring humanized liver tissue for preclinical studies of hepatic pharmacology, metabolism, hepatotoxicity, and HBV-related research.

3Double Humanized Mouse Model
CategoryHumanized Mouse Model
Description

Mouse model reconstituted with both human hematopoietic cells and human liver tissue, enabling combined immune and hepatic preclinical readouts in a single platform.

4Conventional Mouse Models
CategoryConventional Mouse Model
Description

Conventional (non-humanized) mouse models used as comparators and as standalone platforms for syngeneic tumor studies, pharmacology baselines, and routine preclinical in vivo work.

5Oncology Disease Models (CDX, PDX, Syngeneic)
CategoryOncology Disease Model
Description

Preclinical oncology service line providing human cell-line-derived xenograft (CDX), patient-derived xenograft (PDX), and syngeneic tumor mouse models for efficacy, combination, and mechanism studies in oncology drug development.

6Immunology and Inflammation Disease Models (IBD, MASH, GvHD, Lung Inflammation)
CategoryImmunology Disease Model
Description

Preclinical immunology disease model services for inflammatory bowel disease (IBD), MASH, graft-versus-host disease (GvHD), and lung inflammation, supporting efficacy and pharmacodynamic studies of immuno-modulating therapeutics.

7Infectious Disease Models (HIV, HBV)
CategoryInfectious Disease Model
Description

Preclinical HIV and HBV infectious disease studies executed on humanized mouse platforms, supporting antiviral efficacy, mechanism, and immunogenicity readouts for biotech and academic sponsors.

8Hepatotoxicity Assessment Service
CategoryPreclinical Safety Assessment
Description

Preclinical hepatotoxicity assessment service leveraging humanized liver mouse models to evaluate drug-induced liver injury, hepatic enzyme changes, and histopathology for candidate therapeutics.

9Immunotoxicity Assessment Service
CategoryPreclinical Safety Assessment
Description

Preclinical immunotoxicity assessment service combining humanized mouse studies with flow cytometry and immunohistochemistry readouts to characterize immune-mediated effects of drug candidates.

10RADAR Study Tracking Platform
CategoryStudy Management Software
Description

Proprietary RADAR software platform providing clients with real-time visibility into preclinical study progress, milestones, and deliverables across TransCure bioServices' humanized mouse model programs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Taconic Biosciences, a global leader in genetically engineered rodent models, acquired TransCure bioServices SAS in January 2026. The acquisition establishes a fully integrated translational research platform, combining Taconic's global production infrastructure and validated models with TransCure's expertise in disease-specific translational pharmacology, flow cytometry, and advanced in vivo study capabilities. The combined entity supports advanced therapeutic modalities including bi-specific antibodies, CAR-T therapies, and antibody-drug conjugates.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Parent company and most direct comparable: a global leader in genetically engineered rodent models and humanized mouse generation. Since the January 2026 acquisition, Taconic and TransCure operate as a combined translational research platform, making the two directly aligned in business model, customer base, and core technology.

TypeBroad incumbent
Description

A major nonprofit biomedical research institute and one of the largest providers of genetically defined and humanized mouse models worldwide. Overlaps with TransCure on mouse model provision and preclinical services but operates at significantly greater scale and with broader model portfolios.

TypeBroad incumbent
Description

One of the world's largest preclinical CROs, offering a broad menu of rodent research models, discovery, and safety assessment services. Competes with TransCure in humanized mouse and preclinical study services but as part of a much larger full-service preclinical portfolio.

TypeDirect peer
Description

A preclinical CRO specializing in oncology and immuno-oncology translational research, including humanized mouse models, PDX, and CDX platforms. Directly comparable to TransCure on offering (humanized mice for oncology/inflammation/IBD), customer base (biotech sponsors), and study-based CRO business model.

TypeBroad incumbent
Description

A preclinical CRO and research-models provider (formed via Envigo-Harlan consolidation) offering animal models, discovery, and safety assessment services. Competes with TransCure across both model provision and contract research, but at much greater scale.

TypeBroad incumbent
Description

Global CRO/CDMO with preclinical biology capabilities, including humanized mouse model-based efficacy and safety studies. Highly relevant comparable on CRO business model and customer segments, though much larger and more diversified.

TypeEmerging player
Description

A China-based provider of custom mouse models, including humanized immune system models, with growing preclinical services capability. Directly comparable on humanized mouse technology and biotech customer base; smaller global footprint than the major incumbents.

TypeEmerging player
Description

Preclinical CRO offering humanized mouse models, antibody discovery, and in vivo pharmacology services. Comparable in services (humanized mice for immuno-oncology and inflammation) and customer base, with a stronger emphasis on antibody discovery.

TypeDirect peer
Description

A French/European specialist in custom genetically engineered mouse models, including humanized models. Directly comparable on technology (custom mouse model generation) and the European customer base, with stronger custom-model design services rather than full CRO study delivery.

TypeEmerging player
Description

A preclinical CRO offering in vivo and in vitro pharmacology services with focus on oncology and immunology. Comparable on CRO study services and biotech sponsor customer base, with relatively smaller footprint than the largest incumbents.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TransCure bioServices

Preclinical CRO Servicestranscurebioservices.com

TransCure bioServices is a France-based preclinical CRO founded in 2012 that provides humanized mouse models and translational pharmacology services to biotech and pharmaceutical clients developing advanced therapeutics, including antibodies, CAR-T, and ADCs.

What TransCure bioServices does

TransCure bioServices SAS is a France-based preclinical Contract Research Organization founded in 2012 and headquartered in Archamps (registered at the Registry of Thonon-les-Bains). The company specializes in humanized mouse models for translational drug development, offering four core model classes: CD34+ humanized immune system mice, humanized liver mice, double humanized mice combining both systems, and conventional immunodeficient/immunocompetent mice. These models are applied across a portfolio of disease models spanning oncology (human CDX, human PDX, syngeneic), inflammatory disease (IBD, MASH, GvHD, lung inflammation), and infectious disease (HIV, HBV), complemented by hepatotoxicity and immunotoxicity screening services.

The underlying technology platform combines wet-lab biology with an instrumentation stack including three Thermo Fisher Attune NxT flow cytometers, a BD FACS Melody cell sorter, an Aperio Versa digital pathology scanner, a Vilber Newton bioluminescence imaging system, and primary cell culture assays for in vitro mechanism-of-action work. Study operations are supported by RADAR, a custom in-house tracking software for traceability and reproducibility. The company holds AAALAC International accreditation (since 2022), is a GIRCOR charter signatory, and operates a GLP-aligned quality system.

The business model is project-based B2B preclinical CRO services sold through a consultative, sales-led motion targeting biotech and pharmaceutical enterprise clients, with services covering advanced therapeutic modalities including bi-specific antibodies, CAR-T, and antibody-drug conjugates. All 70 collaborators are based in France, and the operating geography has historically been Europe-focused. On January 20, 2026, Taconic Biosciences announced its acquisition of TransCure bioServices, establishing a fully integrated translational research platform that combines Taconic's global rodent model production infrastructure with TransCure's disease-specific translational pharmacology, flow cytometry, and in vivo capabilities.

TransCure bioServices firmographics

Firmographics
Name
TransCure bioServices
Legal name
TransCure BioServices SAS
Website
https://transcurebioservices.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
51–100 employees
Short description
TransCure bioServices is a France-based preclinical CRO founded in 2012 that provides humanized mouse models and translational pharmacology services to biotech and pharmaceutical clients developing advanced therapeutics, including antibodies, CAR-T, and ADCs.
Ownership category
akta.pro rank

TransCure bioServices industry classification

Industry
Product category
Preclinical CRO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)

Keywords

  • Humanized mouse models
  • Preclinical CRO services
  • Translational pharmacology
  • Immunotoxicity assessment
  • Oncology disease models

Where TransCure bioServices is headquartered

Location

Headquarters

HQ city
Archamps
HQ country
France
HQ region
Europe

Offices1 record

Markets served

TransCure bioServices business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

  1. Preclinical CRO Services: Contract research organization providing preclinical studies using humanized mouse models for biotech and pharmaceutical companies. Services include translational pharmacology, flow cytometry, and advanced in vivo study capabilities. Revenue generated through project-based contracts for specific preclinical studies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

TransCure bioServices product offering

Product offering

Core offering

TransCure bioServices is a preclinical contract research organization that designs and executes in vivo pharmacology studies using proprietary humanized and conventional mouse models. It delivers customized preclinical packages — including model selection, study execution, and readouts such as flow cytometry, immunohistochemistry, and in vivo imaging — for biotech, pharmaceutical, and academic sponsors advancing novel therapeutics.

Product overview

TransCure bioServices is a preclinical Contract Research Organization (CRO) offering a portfolio of humanized and conventional mouse models for translational research. The core product line includes four distinct mouse model types: CD34+ Humanized Mouse, Humanized Liver Mouse Model, Double Humanized Mouse Model, and Conventional Mouse Models. These models are applied across multiple disease model categories—Oncology (Human CDX, Human PDX, Syngeneic), Inflammatory diseases (IBD, MASH, GvHD, Lung Inflammation), and Infectious diseases (HIV, HBV). The company also provides dedicated toxicity assessment services (Hepatotoxicity, Immunotoxicity) and general preclinical CRO services. The offering is a services-based portfolio rather than a unified software platform, with models validated over 12 years of experience, now integrated with Taconic Biosciences following acquisition.

Differentiator

Problem solved

Functional benefit

Products and services

  • CD34+ Humanized Mouse Model Humanized mouse model engrafted with human CD34+ hematopoietic stem cells, supplied for and used within preclinical efficacy, immunotoxicity, and mechanism-of-action studies for biotech, pharma, and academic sponsors.
  • Humanized Liver Mouse Model Mouse model harboring humanized liver tissue for preclinical studies of hepatic pharmacology, metabolism, hepatotoxicity, and HBV-related research.
  • Double Humanized Mouse Model Mouse model reconstituted with both human hematopoietic cells and human liver tissue, enabling combined immune and hepatic preclinical readouts in a single platform.
  • Conventional Mouse Models Conventional (non-humanized) mouse models used as comparators and as standalone platforms for syngeneic tumor studies, pharmacology baselines, and routine preclinical in vivo work.
  • Oncology Disease Models (CDX, PDX, Syngeneic) Preclinical oncology service line providing human cell-line-derived xenograft (CDX), patient-derived xenograft (PDX), and syngeneic tumor mouse models for efficacy, combination, and mechanism studies in oncology drug development.
  • Immunology and Inflammation Disease Models (IBD, MASH, GvHD, Lung Inflammation) Preclinical immunology disease model services for inflammatory bowel disease (IBD), MASH, graft-versus-host disease (GvHD), and lung inflammation, supporting efficacy and pharmacodynamic studies of immuno-modulating therapeutics.
  • Infectious Disease Models (HIV, HBV) Preclinical HIV and HBV infectious disease studies executed on humanized mouse platforms, supporting antiviral efficacy, mechanism, and immunogenicity readouts for biotech and academic sponsors.
  • Hepatotoxicity Assessment Service Preclinical hepatotoxicity assessment service leveraging humanized liver mouse models to evaluate drug-induced liver injury, hepatic enzyme changes, and histopathology for candidate therapeutics.
  • Immunotoxicity Assessment Service Preclinical immunotoxicity assessment service combining humanized mouse studies with flow cytometry and immunohistochemistry readouts to characterize immune-mediated effects of drug candidates.
  • RADAR Study Tracking Platform Proprietary RADAR software platform providing clients with real-time visibility into preclinical study progress, milestones, and deliverables across TransCure bioServices' humanized mouse model programs.

Quantifiable outcome

  • Humanized mice engraftment with complete human immune system reconstitution including mature T cells, NK cells, and macrophages
  • +1 more outcomes

Companies that use TransCure bioServices

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

TransCure bioServices technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

TransCure bioServices partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Taconic BiosciencescoreStrategic or Co-development Partner · 20 January 2026Taconic Biosciences, a global leader in genetically engineered rodent models, acquired TransCure bioServices SAS in January 2026. The acquisition establishes a fully integrated translational research platform, combining Taconic's global production infrastructure and validated models with TransCure's expertise in disease-specific translational pharmacology, flow cytometry, and advanced in vivo study capabilities. The combined entity supports advanced therapeutic modalities including bi-specific antibodies, CAR-T therapies, and antibody-drug conjugates.

Scale indicators4 records

Recent moves4 records

Expansion highlights6 records

TransCure bioServices competitors and assessment

Company assessment

Direct peers

  • Taconic Biosciences: Parent company and most direct comparable: a global leader in genetically engineered rodent models and humanized mouse generation. Since the January 2026 acquisition, Taconic and TransCure operate as a combined translational research platform, making the two directly aligned in business model, customer base, and core technology.
  • Crown Bioscience: A preclinical CRO specializing in oncology and immuno-oncology translational research, including humanized mouse models, PDX, and CDX platforms. Directly comparable to TransCure on offering (humanized mice for oncology/inflammation/IBD), customer base (biotech sponsors), and study-based CRO business model.
  • genOway: A French/European specialist in custom genetically engineered mouse models, including humanized models. Directly comparable on technology (custom mouse model generation) and the European customer base, with stronger custom-model design services rather than full CRO study delivery.

Broad incumbents

  • The Jackson Laboratory: A major nonprofit biomedical research institute and one of the largest providers of genetically defined and humanized mouse models worldwide. Overlaps with TransCure on mouse model provision and preclinical services but operates at significantly greater scale and with broader model portfolios.
  • Charles River Laboratories: One of the world's largest preclinical CROs, offering a broad menu of rodent research models, discovery, and safety assessment services. Competes with TransCure in humanized mouse and preclinical study services but as part of a much larger full-service preclinical portfolio.
  • Inotiv: A preclinical CRO and research-models provider (formed via Envigo-Harlan consolidation) offering animal models, discovery, and safety assessment services. Competes with TransCure across both model provision and contract research, but at much greater scale.
  • WuXi AppTec (WuXi Biology): Global CRO/CDMO with preclinical biology capabilities, including humanized mouse model-based efficacy and safety studies. Highly relevant comparable on CRO business model and customer segments, though much larger and more diversified.

Emerging players

  • Cyagen Biosciences: A China-based provider of custom mouse models, including humanized immune system models, with growing preclinical services capability. Directly comparable on humanized mouse technology and biotech customer base; smaller global footprint than the major incumbents.
  • Biocytogen: Preclinical CRO offering humanized mouse models, antibody discovery, and in vivo pharmacology services. Comparable in services (humanized mice for immuno-oncology and inflammation) and customer base, with a stronger emphasis on antibody discovery.
  • Reaction Biology: A preclinical CRO offering in vivo and in vitro pharmacology services with focus on oncology and immunology. Comparable on CRO study services and biotech sponsor customer base, with relatively smaller footprint than the largest incumbents.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

TransCure bioServices social profiles

Digital presence

TransCure bioServices compliance and trust

Trust signal

Compliance3 records

TransCure bioServices financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TransCure bioServices leadership team

Management profile

Number of profiles

Profiles2 records

TransCure bioServices funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TransCure bioServices M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TransCure bioServices

What does TransCure bioServices do?

TransCure bioServices is a preclinical contract research organization that designs and executes in vivo pharmacology studies using proprietary humanized and conventional mouse models. It delivers customized preclinical packages — including model selection, study execution, and readouts such as flow cytometry, immunohistochemistry, and in vivo imaging — for biotech, pharmaceutical, and academic sponsors advancing novel therapeutics.

Is TransCure bioServices a public or private company?

TransCure bioServices is a private company. It is classified as corporate owned and is currently acquired.

When was TransCure bioServices founded?

TransCure bioServices was founded in 2012. It employs 51 to 100 people.

Where is TransCure bioServices based?

TransCure bioServices is headquartered in Archamps, France, in the Europe region.

How does TransCure bioServices make money?

One revenue line is on record: preclinical CRO Services.

Who are TransCure bioServices's main competitors?

Direct peers on record are Taconic Biosciences, Crown Bioscience and genOway. Broad incumbents are The Jackson Laboratory, Charles River Laboratories, Inotiv and WuXi AppTec (WuXi Biology). Emerging players are Cyagen Biosciences, Biocytogen and Reaction Biology.

Does TransCure bioServices have an API?

No public API is recorded for TransCure bioServices.

What industry is TransCure bioServices in?

TransCure bioServices's product category is Preclinical CRO Services. Its primary akta.pro industry code is HLAGADAH, Cell-Based & Potency Assays (Bioassays). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlobal Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsightThe oncology-based in-vivo CRO market is projected to grow from USD 1.5 billion in 2025 to USD 3.2 billion by 2034, a CAGR of ~8%. North America holds the largest share at ~45%, driven by a mature oncology pipeline and outsourcing trends. Growth is fueled by rising cancer burden, advanced animal models, and increased R&D investments.PR NewswireGlobal Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsightThe oncology-based in-vivo CRO market is projected to grow from USD 1.5 billion in 2025 to USD 3.2 billion by 2034, a CAGR of ~8%. North America holds the largest share at 45%, driven by a mature oncology pipeline and outsourcing trends. Growth is fueled by rising cancer burden, advanced animal models, and increased R&D investments.PharmiWeb.comTaconic Biosciences Acquires TransCure bioServices, Building a Comprehensive Global Platform for Humanized Mouse Translational ResearchTaconic Biosciences acquired TransCure bioServices, a provider of preclinical research services involving humanized immune system mouse models, to establish a global research platform. The combined entity will support advanced drug discovery, particularly in immuno-oncology and other next-generation therapies, by integrating models, services, and expertise. This move aims to enhance the efficiency and reliability of translational research for biotech and pharmaceutical companies.Business Wire BlogTaconic Biosciences Acquires TransCure bioServices, Building a Comprehensive Global Platform for Humanized Mouse Translational ResearchTaconic Biosciences, a global leader in genetically engineered rodent models, announced its acquisition of TransCure bioServices SAS, a France-based provider of preclinical research services utilizing humanized immune system mouse models. The acquisition establishes a fully integrated translational research platform, combining Taconic's global production infrastructure and validated models with TransCure's expertise in disease-specific translational pharmacology, flow cytometry, and advanced in vivo study capabilities. The combined entity will support advanced therapeutic modalities including bi-specific antibodies, CAR-T therapies, and antibody-drug conjugates, expanding both companies' geographic footprint and service offerings for biotech and pharmaceutical researchers worldwide.FinSMEsTransCure bioServices Raises €2.5M in FundingTransCure bioServices, a French preclinical services company, raised €2.5M from Financière Arbevel. The funds will accelerate international sales growth in Europe and the USA and expand in vivo preclinical pharmacology services into new product lines.